Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
Board Member
Amneal Pharmaceuticals, Inc. (AMRX)Equibles does not estimate personal net worth.
Get an email with a short summary when Amneal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMRX alertsChintu Patel is recorded as CEO and Board Member at Amneal Pharmaceuticals, Inc. (AMRX). The newest filing on record that lists Chintu Patel as CEO and Board Member at Amneal Pharmaceuticals, Inc. (AMRX) is dated March 25, 2026. The proxy statement of Amneal Pharmaceuticals, Inc. reports total compensation of $8,730,545 for Chintu Patel in fiscal 2025, including a base salary of $800,000. Disclosed compensation is on record for 7 fiscal years. Chintu Patel has spoken on 26 earnings calls across 1 company, most recently for Amneal Pharmaceuticals, Inc. on July 30, 2026. Amneal Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Amneal Pharmaceuticals, Inc. includes Chirag Patel (CEO and Board Member), Paul Meister (Chairman and Board Member), Anastasios (Tasos) G. Konidaris (CFO) and 7 others.
“I would like to thank our MNIL team for another quarter of very strong execution.”
“Let me turn it over to Chin to share more about KaShiv. Thank you, Jirag. Good morning, everyone. Going to slide five, today's acquisition announcement reflects our long stated goal to be vertically integrated in biosimilars.”
“I will begin with gratitude and thank the global MNIL team for their dedication and hard work, which continue to drive our company's success. The formula for strong execution remains the same.”
“Continue to drive our continued strong strategic portfolio capabilities.”
“Let me begin by expressing my deep appreciation to our MNIL team. Your passion, resiliency, and unwavering commitment continues to drive MNIL forward as a deeply purpose-driven company.”
Start not stated–present
Last confirmed March 25, 2026
Start not stated–present
Last confirmed March 25, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer | $800,000 | $8,730,545 |
| 2024 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer | $788,462 | $7,191,109 |
| 2023 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer | $750,000 | $2,367,553 |
| 2022 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer | $750,000 | $5,062,732 |
| 2021 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer | $724,038 | $4,798,825 |
| 2020 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer | $1 | $2,328,528 |
| 2019 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer | $44,226 | $339,600 |